Improved first‐trimester Down syndrome screening performance by lowering the false‐positive rate: a prospective study of 9941 low‐risk women
Open Access
- 25 February 2005
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 25 (3) , 227-233
- https://doi.org/10.1002/uog.1834
Abstract
Objective: To determine the performance of screening for Down syndrome (DS) and other major chromosomal abnormalities using nuchal translucency (NT), free β‐human chorionic gonadotropin (β‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A) in a prospective study of a non‐selected population.Methods: Of 9941 women with an early ultrasound examination, NT was measured in 8622 singleton pregnancies with a gestational age between 10 + 3 and 13 + 6 weeks. β‐hCG and PAPP‐A were analyzed in 6441 cases. Detection rates (DR) and false‐positive rates (FPR) for the NT screening, the double test (β‐hCG and PAPP‐A) and the combined test (NT and the double test) were calculated using a 1 : 250 cut‐off.Results: NT could be measured in 97.5% of cases. The DR for DS with NT screening alone was 75% with a FPR of only 1.8%. The double test detected 73% and the combined test 91%, for FPRs of 8.8% and 2.1%, respectively. We detected 80% of fetuses with other major chromosomal abnormalities with a combination of NT screening and other ultrasound findings. Low β‐hCG and PAPP‐A values (below 0.4 MoM) were observed in 0.5% of the women including all cases of triploidy and trisomy 18 and 13.Conclusions: The performance of a screening strategy for DS using a combination of NT and the double test was superior to that using either NT or the double test alone due to a very low FPR and a higher DR. Copyright © 2005 ISUOG. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- The Danish Medical Research Council
- Copenhagen University
- The John and Birthe Meyer Foundation
- The Ivan Nielsen Foundation
- The Hede Nielsen Foundation
- The Else and Mogens Wedell-Wedellsborg Foundation
- The Dagmar Marshall Foundation
- The Egmont foundation
- The Fetal Medicine Foundation
- The Augustinus Foundation
- The Gangsted Foundation
- The A. P. Møller Foundation
- The Mads Clausens Foundation
- Copenhagen Hospital Corporation
This publication has 37 references indexed in Scilit:
- Screening for triploidy by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- First-trimester screening for Down syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy—the combined testPrenatal Diagnosis, 1999
- Letter. Correct estimation of parameters for ultrasound nuchal translucency screeningPrenatal Diagnosis, 1998
- Evaluation of first-trimester screening by fetal nuchal translucency and maternal agePrenatal Diagnosis, 1998
- Combining Ultrasound and Biochemistry in First-Trimester Screening for Down's syndromePrenatal Diagnosis, 1997
- NUCHAL TRANSLUCENCY CANNOT BE USED AS A SCREENING TEST FOR CHROMOSOMAL ABNORMALITIES IN THE FIRST TRIMESTER OF PREGNANCY IN A ROUTINE ULTRASOUND PRACTICEPrenatal Diagnosis, 1996
- Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free β-hCG and fetal nuchal translucency thicknessUltrasound in Obstetrics & Gynecology, 1995
- First‐trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of ageUltrasound in Obstetrics & Gynecology, 1995
- The implementation of first‐trimester scanning at 10–13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity unitsUltrasound in Obstetrics & Gynecology, 1995
- Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucencyUltrasound in Obstetrics & Gynecology, 1995